These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 27559053)

  • 1. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
    Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
    Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
    [No Abstract]   [Full Text] [Related]  

  • 2. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
    Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
    Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
    [No Abstract]   [Full Text] [Related]  

  • 4. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ.
    Song L; McNeil EM; Ritchie AM; Astell KR; Gourley C; Melton DW
    BMC Cancer; 2017 Dec; 17(1):864. PubMed ID: 29254481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage.
    Giovannini S; Weller MC; Repmann S; Moch H; Jiricny J
    Nucleic Acids Res; 2019 Sep; 47(17):9132-9143. PubMed ID: 31329989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC.
    Sun C; Cao W; Qiu C; Li C; Dongol S; Zhang Z; Dong R; Song K; Yang X; Zhang Q; Kong B
    J Hematol Oncol; 2020 Jan; 13(1):9. PubMed ID: 32005272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
    Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
    Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells.
    Ito S; Murphy CG; Doubrovina E; Jasin M; Moynahan ME
    PLoS One; 2016; 11(7):e0159341. PubMed ID: 27428646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect.
    Vaclová T; Woods NT; Megías D; Gomez-Lopez S; Setién F; García Bueno JM; Macías JA; Barroso A; Urioste M; Esteller M; Monteiro ANA; Benítez J; Osorio A
    Hum Mol Genet; 2016 Dec; 25(24):5287-5299. PubMed ID: 27742776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
    Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
    BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair.
    Wiltshire TD; Lovejoy CA; Wang T; Xia F; O'Connor MJ; Cortez D
    J Biol Chem; 2010 May; 285(19):14565-71. PubMed ID: 20233726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
    Chao OS; Goodman OB
    Mol Cancer Res; 2014 Dec; 12(12):1755-66. PubMed ID: 25127709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
    Lheureux S; Oaknin A; Garg S; Bruce JP; Madariaga A; Dhani NC; Bowering V; White J; Accardi S; Tan Q; Braunstein M; Karakasis K; Cirlan I; Pedersen S; Li T; Fariñas-Madrid L; Lee YC; Liu ZA; Pugh TJ; Oza AM
    Clin Cancer Res; 2020 Aug; 26(16):4206-4215. PubMed ID: 32444417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
    Wichmann C; Klotz DM; Zeiler HJ; Hilger RA; Grützmann K; Krüger A; Aust D; Wimberger P; Kuhlmann JD
    Gynecol Oncol; 2020 Dec; 159(3):850-859. PubMed ID: 32980128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
    Castroviejo-Bermejo M; Cruz C; Llop-Guevara A; Gutiérrez-Enríquez S; Ducy M; Ibrahim YH; Gris-Oliver A; Pellegrino B; Bruna A; Guzmán M; Rodríguez O; Grueso J; Bonache S; Moles-Fernández A; Villacampa G; Viaplana C; Gómez P; Vidal M; Peg V; Serres-Créixams X; Dellaire G; Simard J; Nuciforo P; Rubio IT; Dienstmann R; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Déas O; Jonkers J; Masson JY; Cairo S; Judde JG; O'Connor MJ; Díez O; Balmaña J; Serra V
    EMBO Mol Med; 2018 Dec; 10(12):. PubMed ID: 30377213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
    Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
    Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
    Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.